Switch to:
Also traded in: Australia, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt No Debt
SSH's Cash-to-Debt is ranked higher than
93% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. SSH: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SSH' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.01  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.24
SSH's Equity-to-Asset is ranked lower than
89% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. SSH: 0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
SSH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.91 Max: 0.98
Current: 0.24
0.1
0.98
Piotroski F-Score: 3
Altman Z-Score: -37.81
Beneish M-Score: 35.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1215.05
SSH's Operating Margin % is ranked lower than
94% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. SSH: -1215.05 )
Ranked among companies with meaningful Operating Margin % only.
SSH' s Operating Margin % Range Over the Past 10 Years
Min: -43996.61  Med: -2186.45 Max: -358.24
Current: -1215.05
-43996.61
-358.24
Net Margin % -1225.14
SSH's Net Margin % is ranked lower than
95% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. SSH: -1225.14 )
Ranked among companies with meaningful Net Margin % only.
SSH' s Net Margin % Range Over the Past 10 Years
Min: -45055.93  Med: -2186.45 Max: -358.24
Current: -1225.14
-45055.93
-358.24
ROE % -285.17
SSH's ROE % is ranked lower than
96% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. SSH: -285.17 )
Ranked among companies with meaningful ROE % only.
SSH' s ROE % Range Over the Past 10 Years
Min: -285.17  Med: -137.45 Max: -63.22
Current: -285.17
-285.17
-63.22
ROA % -113.91
SSH's ROA % is ranked lower than
90% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. SSH: -113.91 )
Ranked among companies with meaningful ROA % only.
SSH' s ROA % Range Over the Past 10 Years
Min: -216.94  Med: -110.93 Max: -58.42
Current: -113.91
-216.94
-58.42
ROC (Joel Greenblatt) % -3012.96
SSH's ROC (Joel Greenblatt) % is ranked lower than
91% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. SSH: -3012.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SSH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4851.22  Med: -3243.29 Max: -1516.83
Current: -3012.96
-4851.22
-1516.83
3-Year Revenue Growth Rate 142.00
SSH's 3-Year Revenue Growth Rate is ranked higher than
100% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. SSH: 142.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SSH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -35 Max: 192.2
Current: 142
0
192.2
3-Year EBITDA Growth Rate -25.20
SSH's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. SSH: -25.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SSH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15.1 Max: 418.4
Current: -25.2
0
418.4
3-Year EPS without NRI Growth Rate -19.20
SSH's 3-Year EPS without NRI Growth Rate is ranked lower than
76% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. SSH: -19.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SSH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -17.9 Max: 437.2
Current: -19.2
0
437.2
GuruFocus has detected 4 Warning Signs with Sunshine Heart Inc $SSH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SSH's 10-Y Financials

Financials (Next Earnings Date: 2017-06-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SSH Guru Trades in Q1 2016

Jim Simons 52,881 sh (+46.48%)
» More
Q2 2016

SSH Guru Trades in Q2 2016

Jim Simons 60,000 sh (+13.46%)
» More
Q3 2016

SSH Guru Trades in Q3 2016

Jim Simons 18,100 sh (-69.83%)
» More
Q4 2016

SSH Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SSH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334517    SIC: 3845
Compare:OTCPK:ACAR, OTCPK:VYCO, OTCPK:EQUR, OTCPK:ACXA, OTCPK:MPHMF, OTCPK:AROSF, OTCPK:BIAD, OTCPK:VRSEF, OTCPK:ESMC, OTCPK:IGNG, OTCBB:GTHP, NAS:MDGS, AMEX:NSPR, OTCPK:NUMD, NAS:PHMD, NAS:AHPI, OTCPK:PYNGF, NAS:DYNT, OTCPK:ZYXI, OTCPK:PBIO » details
Traded in other countries:SHC.Australia, 22S1.Germany,
Headquarter Location:USA
Sunshine Heart Inc is a medical device company. It is engaged in developing, manufacturing and commercializing cardiac and coronary disease products.

Sunshine Heart Inc was incorporated in Delaware on August 22, 2002. The company is an early-stage medical device company engaged in developing, manufacturing and commercializing its C-Pulse Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. Its C-Pulse Heart Assist System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. It is in the process of obtaining regulatory approvals necessary to sell its product. Combined, these potential benefits may help reverse the heart failure process or maintain the patient's current condition, thereby potentially preventing the need for later-stage heart failure devices, such as LVADs, artificial hearts or transplants. Its competitors include: AbioMed, Inc., Berlin Heart GmbH, CardioKinetix, Inc., CircuLite, Inc. & HeartWare International Inc. Its business is subject to extensive federal and state government regulation.

Top Ranked Articles about Sunshine Heart Inc

Sunshine Heart Announces Closing of $9.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Sunshine Heart Announces Pricing of $8.0 Million Underwritten Public Offering
Sunshine Heart hires Jim Breidenstein as Chief Commercial Officer
Sunshine Heart Provides Business Update Regarding Execution of Strategic Growth Plan

EDEN PRAIRIE, Minn., March 23, 2017 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH) announced today its progress in successfully executing its Aquadex growth strategy. After acquiring the Aquadex business from Baxter International in August of 2016, the company began executing a revenue growth strategy focused on increasing utilization in the top 55 hospital accounts, which made up 80% of the business. By the end of 2016, there were 95 hospital accounts that have re-engaged and are purchasing the disposable blood sets on a regular basis. As of March 2017, there are now 115 active hospital accounts.
“Our momentum is increasing as we reach more hospital accounts that have been quiet over the past few years,” said John Erb, Chairman of the Board and CEO of Sunshine Heart. Looking ahead, the company is focused on four key areas of growth: Provide better diagnostic tools that will enable healthcare professionals improve patient selection,Generate meaningful economic evidence to support reimbursement and drive utilization,Expand utilization of Aquadex in other areas of the hospital, andExpand the use of Aquadex in an outpatient setting. About Sunshine Heart
Sunshine Heart, Inc. (NASDAQ:SSH) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow® System. The Company's commercial product, the Aquadex system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Our objective is to improve the quality of life for patients with heart failure and related conditions. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012. Forward-Looking Statements
Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, our ability to execute on our recently announced strategic realignment, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses. The risk factors described in our filings with the SEC could cause actual events to adversely differ from the expectations indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sunshine Heart does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Sunshine Heart may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of our therapy, the possibility we may be unable to raise the funds necessary for the development and commercialization of our therapy and other risks and uncertainties described in our filings with the SEC. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:

Claudia Napal Drayton
Chief Financial Officer
Sunshine Heart, Inc.
T: 1-952-345-4205

Investor Relations
Sunshine Heart Inc.
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.37
SSH's PB Ratio is ranked higher than
91% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. SSH: 0.37 )
Ranked among companies with meaningful PB Ratio only.
SSH' s PB Ratio Range Over the Past 10 Years
Min: 0.36  Med: 2.4 Max: 7.09
Current: 0.37
0.36
7.09
PS Ratio 0.41
SSH's PS Ratio is ranked higher than
81% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. SSH: 0.41 )
Ranked among companies with meaningful PS Ratio only.
SSH' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 247.79 Max: 2579.14
Current: 0.41
0.4
2579.14
EV-to-EBIT -0.24
SSH's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. SSH: -0.24 )
Ranked among companies with meaningful EV-to-EBIT only.
SSH' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.6  Med: -1.5 Max: 0.3
Current: -0.24
-4.6
0.3
EV-to-EBITDA -0.26
SSH's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. SSH: -0.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
SSH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.7  Med: -1.5 Max: 0.3
Current: -0.26
-4.7
0.3
Current Ratio 0.74
SSH's Current Ratio is ranked lower than
92% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. SSH: 0.74 )
Ranked among companies with meaningful Current Ratio only.
SSH' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 9.78 Max: 40.76
Current: 0.74
0.74
40.76
Quick Ratio 0.53
SSH's Quick Ratio is ranked lower than
92% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. SSH: 0.53 )
Ranked among companies with meaningful Quick Ratio only.
SSH' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 9.78 Max: 40.76
Current: 0.53
0.53
40.76
Days Inventory 90.00
SSH's Days Inventory is ranked higher than
72% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. SSH: 90.00 )
Ranked among companies with meaningful Days Inventory only.
SSH' s Days Inventory Range Over the Past 10 Years
Min: 90  Med: 173.29 Max: 173.29
Current: 90
90
173.29
Days Sales Outstanding 79.85
SSH's Days Sales Outstanding is ranked lower than
60% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. SSH: 79.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
SSH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.84  Med: 84.17 Max: 803
Current: 79.85
20.84
803

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.70
SSH's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. SSH: -11.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SSH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -112  Med: -25.3 Max: 0
Current: -11.7
-112
0

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -416.67
SSH's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. SSH: -416.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SSH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -431.72  Med: 1287.8 Max: 81137.5
Current: -416.67
-431.72
81137.5

More Statistics

Revenue (TTM) (Mil) $1.29
EPS (TTM) $ -27.06
Beta3.69
Short Percentage of Float14.98%
52-Week Range $0.80 - 48.60
Shares Outstanding (Mil)3.12

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 8 13
EPS ($) -6.00 -1.80
EPS without NRI ($) -6.00 -1.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SSH

Headlines

Articles On GuruFocus.com
Sunshine Heart Announces Closing of $9.2 Million Underwritten Public Offering and Full Exercise of O Apr 24 2017 
Sunshine Heart Announces Pricing of $8.0 Million Underwritten Public Offering Apr 19 2017 
Sunshine Heart hires Jim Breidenstein as Chief Commercial Officer Apr 11 2017 
Sunshine Heart Provides Business Update Regarding Execution of Strategic Growth Plan Mar 23 2017 

More From Other Websites
Express Scripts (ESRX) Earnings Top in Q1, FY17 View Up Apr 25 2017
Sunshine Heart Announces Closing of $9.2 Million Underwritten Public Offering and Full Exercise of... Apr 24 2017
C.R. Bard (BCR) Beats Q1 Earnings & Revenues, FY17 View Up Apr 24 2017
Baxter Launches Drug Library Guide for Smart Infusion System Apr 21 2017
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown Apr 21 2017
Quest Diagnostics (DGX) Tops Q1 Earnings, Raises '17 View Apr 20 2017
Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues Apr 19 2017
Sunshine Heart Announces Pricing of $8.0 Million Underwritten Public Offering Apr 19 2017
Mazor (MZOR) Gets FDA Clearance For Mazor X Align Software Apr 17 2017
Quality Systems (QSII) to Acquire Entrada for $34 Million Apr 13 2017
Accuray TomoTherapy System Starts Cancer Treatment in Africa Apr 12 2017
athenahealth (ATHN) Allies with CoverMyMeds for Faster ePA Apr 11 2017
DaVita Banks on Acquisitions, Escalating Expenses a Concern Apr 11 2017
Masimo (MASI) Launches Root Platform with Kite Trademark Apr 11 2017
Sunshine Heart hires Jim Breidenstein as Chief Commercial Officer Apr 11 2017
AngioDynamics (ANGO) Prices 2.5M Secondary Share Offering Apr 10 2017
Sunshine Heart Receives Nasdaq Listing Extension Mar 29 2017
Sunshine Heart Provides Business Update Regarding Execution of Strategic Growth Plan Mar 23 2017
Today's Research Reports on Stocks to Watch: OraSure Technologies and Sunshine Heart Mar 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)